Journal article
Phospho-(T356)RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
Oncotarget, v 6(22), pp 18863-18874
07 Aug 2015
PMID: 26265441
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Locally advanced squamous cell carcinoma of the head and neck (SCCHN) that is not associated with human papillomavirus (HPV) has a poor prognosis in contrast to HPV-positive disease. To better understand the importance of RB1 activity in HPV-negative SCCHN, we investigated the prognostic value of inhibitory CDK4/6 phosphorylation of RB1 on threonine 356 (T-356) in archival HPV-negative tumor specimens from patients who underwent surgical resection and adjuvant radiation. We benchmarked p(T356)RB1 to total RB1, Ki67, p(T202/Y204)ERK1/2, and TP53, as quantified by automatic quantitative analysis (AQUA), and correlated protein expression with tumor stage and grade. High expression of p(T356)RB1 but not total RB1 predicted reduced overall survival (OS; P = 0.0295), indicating the potential relevance of post-translational phosphorylation. Paired analysis of The Cancer Genome Atlas (TCGA) data for regulators of this RB1 phosphorylation identified loss or truncating mutation of negative regulator CDKN2A (p16) and elevated expression of the CDK4/6 activator CCND1 (cyclin D) as also predicting poor survival. Given that CDK4/6 inhibitors have been most effective in the context of functional RB1 and low expression or deletion of p16 in other tumor types, these data suggest such agents may merit evaluation in HPV-negative SCCHN, specifically in cases associated with high p(T356)RB1.
Metrics
Details
- Title
- Phospho-(T356)RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
- Creators
- Tim N. Beck - Fox Chase Cancer CenterJohn Kaczmar - Fox Chase Cancer CenterElizabeth Handorf - Fox Chase Cancer CenterAnna Nikonova - Fox Chase Cancer CenterCara Dubyk - Fox Chase Cancer CenterSuraj Peri - Fox Chase Cancer CenterMiriam Lango - Fox Chase Cancer CenterJohn A. Ridge - Fox Chase Cancer CenterIlya G. Serebriiskii - Kazan Federal UniversityBarbara Burtness - Yale Cancer CenterErica A. Golemis - Drexel UniversityRanee Mehra - Fox Chase Cancer Center
- Publication Details
- Oncotarget, v 6(22), pp 18863-18874
- Publisher
- Impact Journals Llc
- Number of pages
- 12
- Grant note
- Russian Government Fox Chase Cancer Center Head and Neck Keystone P30CA006927 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) U54 CA149147; R21CA181287; F30 CA180607 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA CA06927 / NIH core grant; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Biochemistry and Molecular Biology
- Web of Science ID
- WOS:000359360000015
- Scopus ID
- 2-s2.0-84938859893
- Other Identifier
- 991019318939804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cell Biology
- Oncology